The investment is set to increase the site’s footprint by nearly 20% to 31,000 square feet, allowing the installation of 35 new freezers
Global pharmaceutical company Catalent has announced a $2.2 million investment in its clinical supply facility in Singapore.
The expansion will see the addition of specialised secondary packaging capabilities for ULT products, enabling the site’s services to support larger packaging campaigns, and increasing capabilities to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines, and cell and gene therapies.
Roel de Nobel, Catalent’s VP and General Manager, said:“Our Singapore site serves as a strategic supply hub for the Asia-Pacific market, offering a wide range of services to customers in over 20 countries in the region.”
This is the latest in a series of investments and expansions that it has undertaken to meet the increasing and diversified demands of customers in their mission
Alongside sites in China and Japan, Catalent’s site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services including clinical supply management, comparator sourcing, Catalent’s FastChain® demand-led supply solution, secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
De Nobel continued: “As the site prepares to mark its 25-year anniversary, this is the latest in a series of investments and expansions that it has undertaken to meet the increasing and diversified demands of customers in their mission to develop life-changing medicines for both the region and the world.”